Table 1 Comparisons of baseline characteristics of patients with FPBC by subtypes.

From: Molecule subtypes play important roles for second primary malignancies development based on 324,661 breast cancer survivors

Characteristics

HR+/HER2-

HR+/HER2+

HR-/HER2+

HR-/HER2-

P value

(Luminal A)

(Luminal B)

(HER2 enriched)

(TNBC)

(N = 245463)(%)

(N = 32922)(%)

(N = 12839)(%)

(N = 33437)(%)

Grade

    

P < 0.01

I

76,284 (31.1%)

2219 (6.7%)

211 (1.6%)

704 (2.1%)

 

II

123,473 (50.3%)

14,019 (42.6%)

3105 (24.2%)

5737 (17.2%)

 

III

45,456 (18.5%)

16,594 (50.4%)

9441 (73.5%)

26,805 (80.2%)

 

IV

250 (0.1%)

90 (0.3%)

82 (0.6%)

191 (0.6%)

 

Histology

    

P < 0.01

Ductal

187,693 (76.5%)

29,152 (88.5%)

11,890 (92.6%)

29,901 (89.4%)

 

Mixed

16,312 (6.6%)

1275 (3.9%)

147 (1.1%)

398 (1.2%)

 

Lobular

29,015 (11.8%)

1312 (4.0%)

109 (0.8%)

361 (1.1%)

 

Other

12,443 (5.1%)

1183 (3.6%)

693 (5.4%)

2777 (8.3%)

 

Subsite

    

P < 0.01

Central portion

11,193 (4.6%)

1621 (4.9%)

596 (4.6%)

1031 (3.1%)

 

Lower-inner quadrant

13,915 (5.7%)

1903 (5.8%)

745 (5.8%)

2039 (6.1%)

 

Lower-outer quadrant

19,060 (7.8%)

2830 (8.6%)

1014 (7.9%)

2403 (7.2%)

 

Upper-outer quadrant

86,631 (35.3%)

11,205 (34.0%)

4391 (34.2%)

13,115 (39.2%)

 

Upper-inner quadrant

32,980 (13.4%)

3855 (11.7%)

1437 (11.2%)

4629 (13.8%)

 

Other

81,684 (33.3%)

11,508 (35.0%)

4656 (36.3%)

10,220 (30.6%)

 

Age of diagnosis

    

P < 0.01

young

9608 (3.9%)

2978 (9.0%)

1087 (8.5%)

3154 (9.4%)

 

middle

136,746 (55.7%)

20,805 (63.2%)

8281 (64.5%)

19,786 (59.2%)

 

old

99,109 (40.4%)

9139 (27.8%)

3471 (27.0%)

10,497 (31.4%)

 

Laterality

    

P < 0.01

Left

123,674 (50.4%)

16,750 (50.9%)

6620 (51.6%)

17,041 (51.0%)

 

Right

121,789 (49.6%)

16,172 (49.1%)

6219 (48.4%)

16,396 (49.0%)

 

Radiotherapy

    

P < 0.01

NRT

93,208 (38.0%)

14,308 (43.5%)

6074 (47.3%)

14,061 (42.1%)

 

RT

152,255 (62.0%)

18,614 (56.5%)

6765 (52.7%)

19,376 (57.9%)

 

Size

    

P < 0.01

< 2 cm

164,593 (67.1%)

17,448 (53.0%)

6148 (47.9%)

15,352 (45.9%)

 

> 2 cm,< 5 cm

66,503 (27.1%)

12,246 (37.2%)

4847 (37.8%)

14,284 (42.7%)

 

> 5 cm

14,367 (5.9%)

3228 (9.8%)

1844 (14.4%)

3801 (11.4%)

 

Clinical lymph node status

    

P < 0.01

0 positive

179,243(73.02)

20,984(63.74)

7732(60.22)

23,052(68.94)

 

≥ 1 positive

66,220(26.98)

11,938(36.26)

5170(39.78)

10,385(31.06)

 

Pathological stage

    

P < 0.01

I stage

147,083(59.92)

14,762(44.84)

4811(37.47)

12,851(38.43)

 

II stage

77,453(31.55)

13,544(41.14)

5591(43.55)

15,697(46.95)

 

III stage

20,927(8.53)

4616(14.02)

2437(18.98)

4889(14.62)

 

Chemotherapy

    

P < 0.01

No/Unknown

175,827 (71.6%)

7785 (23.6%)

2503 (19.5%)

7404 (22.1%)

 

Yes

69,636 (28.4%)

25,137 (76.4%)

10,336 (80.5%)

26,033 (77.9%)

 

Married Stage

    

P < 0.01

Married

208,436 (84.9%)

27,209 (82.6%)

10,696 (83.3%)

27,472 (82.2%)

 

Single

37,027 (15.1%)

5713 (17.4%)

2143 (16.7%)

5965 (17.8%)

 

Survival time(months)

    

P < 0.01

Mean (SD)

48.1 (30.3)

49.1 (29.4)

49.5 (29.4)

47.8 (30.1)

 

Median [Min, Max]

46.0 [0, 107]

46.0 [0, 107]

46.0 [0, 107]

44.0 [0, 107]

 

Age of diagnosis(Year)

    

P < 0.01

Mean (SD)

60.6 (12.1)

56.5 (12.6)

56.8 (12.3)

57.4 (13.1)

 

Median [Min, Max]

61.0 [20.0, 85.0]

56.0 [20.0, 85.0]

56.0 [21.0, 85.0]

58.0 [20.0, 85.0]

 

Latency

    

0.17

Median(months)

39

39

40

41

 
  1. Latency: the time from first breast diagniosi to the SPMs diagnosis; young group:< 40 years old; middle group: 40–64 years old; old group: > 65 years old
Back to article page